Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Foghorn Therapeutics (FHTX) has issued an announcement.
Foghorn Therapeutics Inc. has appointed Kristian F. Humer as their new Chief Financial Officer, bringing a wealth of experience from his previous role at Viridian Therapeutics and a strong background in healthcare investment banking with Citi, Lehman Brothers, UBS, and Merrill Lynch. Humer, who also serves on the board of Sensei Biotherapeutics, will receive a competitive compensation package, including a $475,000 base salary, potential for a 40% performance bonus, a $87,000 signing bonus, and an option to purchase 275,000 company shares. His appointment, effective immediately, marks a strategic move for Foghorn as they navigate the financial landscape of the biotechnology sector.
See more insights into FHTX stock on TipRanks’ Stock Analysis page.
